Does TRT Cause Prostate Cancer? What 80 Years of Research Actually Shows

The fear of testosterone and prostate cancer traces back to a single experiment in 1941, and understanding why that experiment led medicine in the wrong direction for eight decades requires understanding what the prostate actually does with testosterone in the first place.

Your prostate depends on androgens, which are hormones like testosterone, to function and grow. That much has always been true. When Charles Huggins castrated men with advanced prostate cancer in 1941 and watched their cancer markers fall, and then injected testosterone back in and watched those markers rise again, the conclusion seemed obvious: testosterone feeds prostate cancer, so more testosterone must cause it. Huggins won the Nobel Prize for this work. The medical community locked in the belief. And for most of the next 80 years, doctors told men that testosterone therapy was a risk they should not take.

The problem is that the conclusion was drawn from men who had essentially zero testosterone in their system, and the prostate behaves very differently at the bottom of that range than it does anywhere above it.

Here is the mechanism that changes everything. The prostate has a limited number of androgen receptors, which are the proteins that bind to testosterone and trigger a cellular response. Once those receptors are fully occupied, adding more testosterone produces almost no additional effect on the prostate. The receptors are already saturated. This concept is called the saturation model, and the research behind it shows that saturation occurs at roughly 240 to 250 nanograms per deciliter of testosterone. Below that threshold, changes in testosterone have a dramatic effect on prostate tissue. Above it, the dose-response relationship essentially disappears.

Think of it like a parking lot that holds 100 cars. When there are only 10 cars parked, adding 10 more makes a real difference. When the lot is full, a hundred more cars circling the block changes nothing inside the lot.

A man with healthy testosterone levels already sits well above 250 nanograms per deciliter. A man on TRT sits above it. The threshold was identified in castrated men, which is why injecting testosterone back into Huggins' patients caused such a dramatic response: those men were below the saturation point, so the added testosterone had a massive effect. That observation was real. The error was in generalizing that finding to men who already have functional testosterone levels, which is a completely different physiological context.

So when researchers actually ran the trials on men receiving TRT, the findings were consistent across a large body of evidence. The largest randomized trial followed 5,204 men with hypogonadism for 33 months and found prostate cancer in 0.46 percent of the TRT group versus 0.42 percent in the placebo group, a difference so small it was not statistically significant at all, with a hazard ratio of 1.07 and a p-value of 0.87. A population study following 78,615 Finnish men for 18 years found not just no increased risk, but that prostate cancer-specific mortality was actually lower in TRT users, with a hazard ratio of 0.52, meaning TRT users were roughly half as likely to die from prostate cancer as non-users. A meta-analysis pooling 28 randomized controlled trials found that PSA, which is a blood marker called prostate-specific antigen that reflects prostate cell activity, rose by an average of 0.08 nanograms per milliliter in men on TRT. For context, that is a change so small it falls within normal day-to-day variation and has no clinical meaning. Urinary symptom scores across those same trials showed a change of exactly zero.

The most direct test of the hypothesis, though, is what happens when you give testosterone to men who already have prostate cancer. If testosterone causes prostate cancer to grow, men with existing cancer should see rapid progression when exposed to it. A study of 69,984 men who had already been treated for localized prostate cancer included 1,012 who subsequently received TRT. There was no increase in recurrence and no increase in death. That is a harder result to dismiss than any population correlation, because it directly tests the mechanism the 1941 hypothesis depends on.

The practical takeaway from all of this is not that prostate health is irrelevant on TRT, but that the monitoring approach should match the actual risk. Before starting testosterone therapy, get a baseline PSA. That baseline is your reference point. Check it again at three to six months after starting, and then once a year from there. If PSA climbs more than 1.4 nanograms per milliliter above your individual baseline, that warrants a conversation with a urologist, not because TRT caused a problem, but because any significant PSA shift in any man deserves investigation regardless of what medications he is taking. The 1.4 threshold comes from Endocrine Society clinical guidelines and reflects a meaningful departure from baseline rather than normal fluctuation.

What is worth sitting with here is how the original 1941 finding was never wrong in what it observed. Castration lowered cancer markers. Testosterone injection raised them back. That data was accurate. But it described a system operating in an extreme state, castrate levels of testosterone, and the error was in applying that observation to men whose prostate androgen receptors were already saturated. It is the same kind of reasoning as concluding that because dehydration raises heart rate, drinking water must cause tachycardia. The direction of the relationship is real in the extreme state. The extrapolation to normal physiology is where the logic broke.

Eight decades of clinical inertia built on a single experiment in a population of castrated men is not a small thing to unwind, but the data is now large enough that the picture is clear.

---

References

1. Huggins CV, Hodges CV. 1941. "Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate." Cancer Research. 14:293-297. Finding: Castration reduced acid phosphatase in men with metastatic prostate cancer; testosterone injection into castrated men raised it back. Source
2. Morgentaler A, Traish AM. 2009. "Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth." European Urology. 552:310-320. Finding: Prostate androgen receptors saturate at approximately 240-250 ng/dL; above this threshold, additional testosterone produces minimal prostate effect. Source
3. Bhasin S, Travison TG, Pencina KM, et al. 2023. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial." JAMA Network Open. 612:e2348692. Finding: 5,204 men, 33 months. Prostate cancer: 0.46% TRT vs 0.42% placebo HR 1.07, p=0.87. No significant difference. Source
4. Siltari A, Murtola TJ, Kausz J, et al. 2023. "Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men." Acta Oncologica. 6211-12:1755-1762. Finding: 78,615 men, 18-year follow-up. Prostate cancer-specific mortality LOWER in TRT users HR 0.52. Source
5. Xu Z, Chen X, Zhou H, et al. 2024. "An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate." Frontiers in Endocrinology. 15:1335146. Finding: 28 RCTs. PSA change: 0.08 ng/mL not significant. IPSS change: 0.00 literally zero difference. Source
6. Sarkar RR, Patel SH, Parsons JK, et al. 2021. "Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease." Prostate Cancer and Prostatic Diseases. 24:739-746. Finding: 69,984 men with treated prostate cancer, 1,012 received TRT. No increase in recurrence or death. Source
7. Bhasin S, Brito JP, Cunningham GR, et al. 2018. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." JCEM. 1035:1715-1744. Finding: Refer to urology if PSA rises >1.4 ng/mL above baseline. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness